Promotion of Mitochondrial Biogenesis by Necdin Protects Neurons against Mitochondrial Insults
Scientists identified necdin as a potent PGC-1α stabilizer that promotes mitochondrial biogenesis via PGC-1α in mammalian neurons. Expression of genes encoding mitochondria-specific proteins decreases significantly in necdin-null cortical neurons, where mitochondrial function and expression of the PGC-1α protein are reduced. [Nat Commun] Full Article
Enrichment of Oligodendrocyte Progenitors from Differentiated Neural Precursors by Clonal Sphere Preparations
To make clonal neurospheres from human embryonic stem cell (ESC)/induced pluripotent stem cell (iPSC) colonies, scientists found that a monolayer differentiation phase helps to increase the numbers of neural precursor cells. They compared a direct isolation of neural stem cells from human ESC/iPSCs colonies with monolayer neural differentiation, followed by clonal neural stem cell sphere preparations. [Stem Cells Dev] Abstract
Role of Docosahexaenoic Acid in the Modulation of Glial Cells in Alzheimer’s Disease
Since docosahexaenoic acid (DHA) can modulate glial cell activity, the authors review the evidence about this modulation as well as the effect of docosanoids on neuroinflammation and in some Alzheimer’s disease (AD) models. The evidence supports peroxisome proliferator-activated receptor γ as a preferred target for gene modulation. The effective use of DHA and/or its derivatives in a subgroup of people at risk of developing AD is discussed. [J Neuroinflammation] Full Article
Visit our reviews page to see a complete list of reviews in the neural cell research field.
INDUSTRY NEWS
BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403
BioInvent International and Oncurious NV announced that the companies have signed a partnership with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). Accessing the NMRTC network of specialist clinicians will serve to accelerate the enrollment of patients to the planned Phase I/IIa trial of TB-403 in pediatric patients with rare but life threatening cancers; medulloblastoma, neuroblastoma, and Ewing’s sarcoma. [BioInvent International AB] Press Release
FDA Grants Second Orphan Designation for VAL-083
DelMar Pharmaceuticals, Inc. announced that the FDA Office of Orphan Products Development has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma. [DelMar Pharmaceuticals, Inc.] Press Release
Recruit Top Talent: Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Neural Cell News? Click here to submit!